Drug Profile

Pioglitazone - Transparency Life Sciences

Alternative Names: PPAR activator (pioglitazone) - Transparency Life Sciences

Latest Information Update: 15 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Developer Transparency Life Sciences
Class Antihyperglycaemics; Small molecules; Thiazolidinediones
Mechanism of Action Inflammation mediator modulators; Monoamine oxidase inhibitors; Peroxisome proliferator-activated receptor gamma agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in USA
19 Dec 2012 Early research in Parkinson's disease in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com